SFDA Issues Anti-Counterfeiting Rules for CMOs

To thwart drug counterfeiting, the SFDA has tightened up some regulations on contract manufacturing organizations, notably on rules governing cross-border interactions. Most significantly, the SFDA will no longer allow third-parties to operate between a CMO and the pharma that holds the marketing authorization for a product. The contact between the CMO and a foreign pharma must be direct. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});